Article
The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer.
Nature medicine - 1 May 1995
Ellis J R, Keating P J, Baird J, Hounsell E F, Renouf D V, Rowe M, Hopkins D, Duggan-Keen M F, Bartholomew J S, Young L S
Abstract excerpt
HLA-restricted cytotoxic T-lymphocyte (CTL) recognition of human papillomavirus (HPV) oncogene products may be important in the control of the HPV infections associated with the development of cervical cancer. We have identified, in HLA-B7 individuals, a consistent variation in the HPV16 E6 oncoprotein sequence, which alters an HLA-B7 peptide binding epitope in a way likely to influence immune recognition by...
Topics
- Amino Acid Sequence
- Epitopes
- Female
- HLA-B7 Antigen
- Humans
- Molecular Sequence Data
- Mutation
- Oncogene Proteins, Viral
- Papillomaviridae
- Protein Binding
- Repressor Proteins